glp-1 obesity drug news october 2025 today Outlook for obesity in 2025: more than a transition year 2024 was a record year

Description

revising it critically for important intellectual content

Qiao L, Saget S, Lu C, Zang T, Dzyuba B, Hay WW, Shao J

E.MontanyaE.BrettJ

Some of those drugs are further along in development than Gubra's medicine, such as Zealand's petrelintide, but it is still too early to know which one is most effective for weight loss

This resource includes hand-crafted patent highlights featuring synthetically lethal Pol inhibitors from linkedin_mention(urn:li:organization:1603|AstraZeneca) and linkedin_mention(urn:li:organization:1399|GSK) , SARM1 Inhibitors for neurodegenerative indications and our best guess at the identity of linkedin_mention(urn:li:organization:163993|Gilead Sciences) ' small molecule GLP-1R agonist GS-4571 Full article |